Physician profile
Sonak B Daulat
NPI 1316904824
$72,144.21
in general payments reported to CMS, 2019-2025
31 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,635 · 2021: $4,485 · 2022: $14K · 2023: $4,389 · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $4,971 · Travel and Lodging: $2,887 · Education: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,960.00 |
| Food and Beverage | $4,971.23 |
| Travel and Lodging | $2,886.94 |
| Education | $220.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $61,671.01 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $3,274.87 | 2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals LP | $1,907.47 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,027.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $594.40 | 2019-2025 | Dupixent |
| Genzyme Corporation | $482.44 | 2021-2025 | |
| Pfizer INC. | $466.04 | 2019-2025 | |
| Grifols USA, LLC | $323.74 | 2022-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $297.86 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $289.89 | 2020-2025 | Takhzyro, Cuvitru |
| Octapharma USA, INC. | $253.22 | 2020-2024 | Cutaquig |
| Sanofi-Aventis U.S. LLC | $239.51 | 2019-2023 | |
| Covis Pharma Gmbh | $227.30 | 2020-2022 | |
| Blueprint Medicines Corporation | $129.95 | 2023-2025 | Ayvakit |
| Amgen INC. | $124.94 | 2022-2025 | Tezspire, Actimmune |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $119.11 | 2020-2023 | Auvi-Q |
| Csl Behring | $109.25 | 2019-2025 | Hizentra, Privigen |
| Pharming Healthcare, INC. | $106.67 | 2022-2024 | Ruconest |
| Hikma Pharmaceuticals USA | $94.33 | 2023-2024 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $85.26 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.62 | 2020-2021 | |
| Ars Pharmaceuticals Operations, INC. | $52.17 | 2025 | Neffy |
| Alk-Abello, INC | $48.23 | 2019-2021 | |
| Hospira, INC. | $29.27 | 2024-2025 | |
| Genentech USA, INC. | $26.10 | 2021-2022 | |
| Abbvie INC. | $17.95 | 2023 | Rinvoq |
| Merck Sharp & Dohme LLC | $16.74 | 2023 | |
| Shire North American Group INC | $15.82 | 2019 | |
| Boston Scientific Corporation | $15.71 | 2025 | Enhance Transcarotid Peripheral Access Kit |
| Lilly USA, LLC | $14.04 | 2025 | Ebglyss |
| Philips North America LLC | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonak Daulat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.